Ikena therapeutics
Web7 mrt. 2024 · Dr. Jeff Ecsedy, Ikena’s Chief Development Officer, will present data supporting the potential of IK-930 as a clinical agent during a minisymposium on experimental and molecular cancer therapeutics. WebBackground. NTRK fusions are actionable biomarkers with efficient and well tolerated TRKis. Clinical profile and outcomes of pts with NTRK+ tumours receiving non-TRKi SoC are unknown and the prognosis of NTRK+ pts vs pts with NTRK fusion-negative (NTRK–) tumours is not well known.
Ikena therapeutics
Did you know?
Web7 okt. 2024 · Pioneering treatments for neurodegenerative diseases. Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source. Atalanta's. branched siRNA. Web8 dec. 2024 · Michelle Zhang, Ph.D., joined Ikena (then Kyn Therapeutics) in 2016 as Vice President, Research and Development and was later promoted to Senior Vice President, ...
Web7 mrt. 2024 · Ikena is advancing IK-930 both as a monotherapy in patients with Hippo pathway mutated cancers and in combination with other approved targeted therapies to … Web24 mrt. 2024 · Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. ... Ikena Oncology Financials. Summary financials. Revenue (Q3, 2024)$6.4M Net income (Q3, 2024)($17.3M) Cash (FY, 2024)$59.9M EBIT (Q3, 2024)
Web17 dec. 2024 · The new name, “Ikena,” is derived from the combination of “i” which refers to the individual patient and “ken” which means knowledge, thereby illustrating our focus on … WebIkena is redefining the targeted oncology landscape and envisioning a world in which every cancer patient has a cure, guided by a deep understanding of the patient experience and …
Web21 uur geleden · Ikena Oncology. 8,517 followers. 1y. Our president and CEO Mark Manfredi, Ph.D., discussed Ikena’s unique corporate culture and goal to create a vibrant, innovative environment for employees to ...
Web26 mrt. 2024 · Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins … dhafer with clarinetWeb5 sep. 2024 · Arrys Therapeutics: ClinicalTrials.gov Identifier: NCT03658772 Other Study ID Numbers: ARYS-001 Keynote-878 ( Other Identifier: Merck Sharp & Dohme Corp. ) First Posted: September 5, 2024 Key Record Dates: Last Update Posted: April 22, 2024 Last Verified: April 2024 dhafir engineering servicesWeb5 jan. 2024 · Their stock opened with $16.00 in its Mar 26, 2024 IPO. Ikena Oncology is funded by 12 investors. Bristol Myers Squibb and Cowen Healthcare Investments are the most recent investors. Ikena Oncology has a post-money valuation in the range of $500M to $1B as of Jan 6, 2024, according to PrivCo. Sign up for a free trial to view exact … cid 10 f 71Web24 mrt. 2024 · Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. It develops … cid 10 f70-0WebAlso Known As Kyn Therapeutics. Legal Name Ikena Oncology, Inc. Stock Symbol NASDAQ:IKNA. Company Type For Profit. Contact Email [email protected]. Phone Number +1 857 273 8343. Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation … cid 10 f88WebKyn Therapeutics is advancing development programs with targets strongly implicated in immunosuppression across a range of tumor types and via multiple immune cell effects. … cid 10 f82WebIkena Oncology (formerly Kyn Therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed therapies for cancer patients, by understanding what drives their disease. Ikena leverages core capabilities in oncology drug discovery, translational sciences and clinical development to build a next generation ... cid 10 f 83